CINECA IRIS Institutional Research Information System

FERRERO, Simone
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.050
EU - Europa 3.229
AS - Asia 1.257
SA - Sud America 66
OC - Oceania 63
AF - Africa 35
Continente sconosciuto - Info sul continente non disponibili 4
Totale 8.704
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.963
IT - Italia 1.043
CN - Cina 566
IE - Irlanda 395
SE - Svezia 366
FR - Francia 243
KR - Corea 192
AT - Austria 190
DE - Germania 173
GB - Regno Unito 137
UA - Ucraina 103
DK - Danimarca 100
VN - Vietnam 87
JP - Giappone 84
FI - Finlandia 79
BE - Belgio 75
IN - India 74
ES - Italia 70
TR - Turchia 67
PL - Polonia 60
AU - Australia 58
CA - Canada 54
NL - Olanda 40
TH - Thailandia 39
CH - Svizzera 38
GR - Grecia 36
HK - Hong Kong 35
MX - Messico 25
SN - Senegal 21
PT - Portogallo 20
SA - Arabia Saudita 17
BR - Brasile 15
NO - Norvegia 14
PE - Perù 14
RU - Federazione Russa 14
SG - Singapore 14
CL - Cile 13
TW - Taiwan 13
IL - Israele 12
UZ - Uzbekistan 12
IR - Iran 11
AR - Argentina 9
PH - Filippine 7
PK - Pakistan 7
RO - Romania 7
CZ - Repubblica Ceca 6
BY - Bielorussia 5
NZ - Nuova Zelanda 5
CO - Colombia 4
EC - Ecuador 4
EU - Europa 4
MY - Malesia 4
PR - Porto Rico 4
BD - Bangladesh 3
BO - Bolivia 3
EG - Egitto 3
HR - Croazia 3
HU - Ungheria 3
PS - Palestinian Territory 3
VE - Venezuela 3
DZ - Algeria 2
GH - Ghana 2
GT - Guatemala 2
MU - Mauritius 2
OM - Oman 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
CU - Cuba 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ID - Indonesia 1
IQ - Iraq 1
JO - Giordania 1
KW - Kuwait 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MM - Myanmar 1
MN - Mongolia 1
RS - Serbia 1
SI - Slovenia 1
UY - Uruguay 1
Totale 8.704
Salva come PNG Salva come JPEG
Città #
Chandler 617
Dublin 391
Beijing 310
Torino 261
Fairfield 242
Ann Arbor 191
Vienna 188
Wilmington 152
Houston 147
Nyköping 141
Ashburn 130
Dearborn 117
Villeurbanne 116
Woodbridge 116
Medford 111
Cambridge 93
Princeton 93
Redwood City 79
Florence 78
San Mateo 78
Seattle 77
Jacksonville 71
Brussels 61
Turin 59
Fremont 58
Milan 51
Dong Ket 49
Rome 47
Pisa 41
Washington 38
Boston 32
Warsaw 32
Guangzhou 28
Sydney 27
Chennai 25
Bologna 24
London 23
Hebei 21
Shanghai 21
Hangzhou 19
Istanbul 19
Nanjing 19
Central 18
Toronto 18
Norwalk 17
San Diego 17
Bangkok 16
Chengdu 16
Barcelona 15
Boardman 15
Tokyo 15
Lima 14
Seoul 14
Athens 13
Madrid 13
Atlanta 12
Taipei 12
Melbourne 11
Mountain View 11
Ottawa 11
Rochester 11
Philadelphia 10
Zhengzhou 10
Amsterdam 9
Ankara 9
Duncan 9
Hefei 9
Xian 9
Berlin 8
Chicago 8
Diyarbakir 8
Falls Church 8
Hat Yai 8
Los Angeles 8
Nagareyama 8
Naples 8
Padova 8
Palermo 8
Polska 8
Redmond 8
Saint Petersburg 8
Bilbao 7
Guiyang 7
Jinan 7
Lisbon 7
Munich 7
Nanchang 7
Oslo 7
Rotterdam 7
San Antonio 7
San Jose 7
Santiago 7
Utrecht 7
Zurich 7
Central District 6
Düsseldorf 6
Genoa 6
Hanover 6
Lausanne 6
Monza 6
Totale 5.058
Salva come PNG Salva come JPEG
Nome #
ABVD vs BEACOPP escalated in advanced-stage Hodgkin’s lymphoma: Results from a multicenter European study 749
Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi 514
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data 371
Early progression as a predictor of survival in marginal zone lymphomas: An analysis from the FIL-NF10 study 291
Maternal and Perinatal Outcomes of Pregnant Women with SARS-COV-2 infection 268
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma 243
Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach? 224
Novel CALR somatic mutations in essential thrombocythaemia 222
Prospective molecular monitoring of minimal residual disease after nonmyeloablative allografting in newly diagnosed multiple myeloma 186
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis 176
Highly sensitive MYD88 l265p mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia 176
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 161
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the "Fondazione Italiana Linfomi" MCL-0208 trial 150
A 6-GENE EXPRESSION SIGNATURE IN MANTLE CELL LYMPHOMA: RESULTS FROM THE FONDAZIONE ITALIANA LINFOMI (FIL)-MCL-0208 TRIAL 149
New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies 121
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 116
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi (FIL) ensures superior data quality and improved assessment of clinical outcomes. 116
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 113
Psychological distress and oral chemotherapy: a pilot study. 112
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 102
Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases 100
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study 99
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR 95
COMPREHENSIVE ANALYSIS OF BASELINE OUTCOME BIOPREDICTORS IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: THE ANCILLARY BIOLOGICAL STUDIES OF FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 CLINICAL TRIAL 93
MYD88L265P MUTATION DETECTION IN WALDENSTRÖM MACROGLOBULINEMIA BY DROPLET DIGITAL PCR: MINIMAL RESIDUAL DISEASE MONITORING AND CHARACTERIZATION ON CIRCULATING FREE DNA 93
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi 93
Delphi, a Data Warehouse to Discover Associations between Variables in Clinical Trials: Application to the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 90
Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone 89
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia 89
Droplet digital PCR for minimal residual disease detection in mature lymphoproliferative disorders 89
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival 87
Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia 87
Italian real life experience with ibrutinib: Results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 86
The Engineered MIPI (e-MIPI), a Candidate Data-Mining Based Mantle Cell Lymphoma Prognostic Index Developed from the Dataset of the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 85
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines 83
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 79
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 78
Droplet Digital PCR Assay for MYD88L265P 77
Oral chemotherapy: an innovative choice 76
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma 76
Real life use of bendamustine in elderly patients with lymphoid neoplasia 76
Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients 75
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL 70
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia 69
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 68
Minimal Residual Disease in Indolent Lymphomas: A Critical Assessment 68
Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Trasplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study 67
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia 67
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network 67
PERSONALIZED MEDICINE IN LYMPHOMA: TAILORING TREATMENT ACCORDING TO MINIMAL RESIDUAL DISEASE 66
Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study 65
null 64
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 64
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders 63
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma 63
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi 62
Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study 60
MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL) 60
Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: Final results of a European MCL Network Phase II Trial 58
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells 55
A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL) 54
Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms 53
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation 52
Application of the Euro Clonality next-generation sequencing-based marker screening approach to detect immunoglobulin heavy chain rearrangements in mantle cell lymphoma patients: first data from the Fondazione Italiana Linfomi MCL0208 trial 52
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? 51
Droplet digital PCR quantification of mantle cell lymphoma follow-up samples from four prospective trials of the european MCL network 48
COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment 48
HIGH RATES OF PROLONGED MOLECULAR REMISSIONS AFTER TANDEM AUTOLOGOUS-NONMYELOABLATIVE ALLOGRAFTING IN NEWLY DIAGNOSED MYELOMA 47
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease 47
Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. 46
Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue 45
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma 43
SYNDECAN-1 PROMOTES THE ANGIOGENIC PHENOTYPE OF MULTIPLE MYELOMA ENDOTHELIAL CELLS 42
The challenge of treating elderly patients with mantle cell lymphoma 42
Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: A phase II clinical trial of the fondazione italiana linfomi 41
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma 41
How to treat old MCL patients: One size fits it all? 39
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 38
MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation 36
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase III trial in mantle cell lymphoma 36
The role of targeted treatment in mantle cell lymphoma: Is transplant dead or alive? 34
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma 34
Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy 34
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder 33
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi 33
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study 32
The current therapeutic scenario for relapsed mantle cell lymphoma 30
Personalized medicine in lymphoma: Is it worthwhile? The mantle cell lymphoma experience 29
How to manage mantle cell lymphoma 27
Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial 25
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial 23
New paradigms in mantle cell lymphoma: Is it time to risk-stratify treatment based on the proliferative signature? 22
Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network 21
Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports 21
HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience 18
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program 18
Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up 14
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. 14
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease 14
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance 14
Totale 9.002
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.685
article - articoli 0
book - libri 0
conference - conferenze 4.094
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.779
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019403 0 0 0 32 29 22 41 79 12 59 84 45
2019/20201.010 17 17 33 125 73 139 104 83 106 98 119 96
2020/20211.309 126 75 141 64 121 77 75 82 124 102 110 212
2021/20221.813 77 68 109 164 113 109 204 110 86 175 352 246
2022/20232.662 208 221 76 229 226 528 237 197 270 150 143 177
2023/2024596 174 265 155 2 0 0 0 0 0 0 0 0
Totale 9.028